A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 543-552

  Homesley, Howard D ^a   Filiaci, Virginia ^b   Gibbons, Susan K ^c   Long, Harry J ^d   Cella, David ^e   Spirtos, Nick M ^f   Morris, Robert T ^g   DeGeest, Koen ^h   Lee, Roger ⁱ   Montag, Anthony ^j  

^a EAST CAROLINA UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^f UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

ⁱ Tacoma General Hospital   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

Advanced endometrial carcinoma; Radiation and chemotherapy; Surgery

Indexed keywords

CESIUM; CISPLATIN; COBALT; DEXAMETHASONE; DOXORUBICIN; GROWTH FACTOR; IRIDIUM; PACLITAXEL; RADIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3A RECEPTOR;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HISTOLOGY; HUMAN; INFECTION; IRRADIATION; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARAAORTIC LYMPH NODE; PELVIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY;

EID: 60449095359     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.014     Document Type: Article

References (25)

1. Greer B., and Hamberger A. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole abdomen moving strip technique and pelvic boost irradiation. Gynecol. Oncol. 16 (1983) 365-373
2. Leoffler J., Rosen E., Niloff J., Howes A., and Knapp R. Whole abdominal irradiation for tumors of the uterine corpus. Cancer 61 (1988) 1223-1235
3. Martinez A., Schray M., Podratz K., Stanhope R., and Malkasian G. Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 17 (1989) 371-377
4. Gibbons S., Martinez A., Schray M., et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 21 (1991) 1019-1025
5. Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H., Lee R.B., et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 100 (2006) 349-354
6. Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H.D., Malfetano J.H., et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 97 (2005) 755-763
7. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 22 (2004) 3902-3908
8. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 24 (2006) 36-44
9. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 277-281
10. Pickel H., Lahousen M., Petru E., Stettner H., Hackl A., Kapp K., et al. Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol. Oncol. 72 (1999) 215-219
11. Reisinger S.A., Asbury R., Liao S.Y., and Homesley H.D. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. Gynecol. Oncol. 63 (1996) 299-303
12. Soper J.T., Reisinger S.A., Ashbury R., Jones E., and Clarke-Pearson D.L. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial. Gynecol. Oncol. 95 (2004) 95-100
13. Schoenfeld D.A. Sample size formula for the proportional hazards regression model. Biometrics 39 (1983) 499-503
14. DeMets D.L., and Lan G. The alpha spending function approach to interim data analyses. In: Thall P.F. (Ed). Recent advances in clinical trial design and analysis (1995), Kluwer Academic Publishers, Boston 1-27
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo. Rep. 50 (1966) 163-170
16. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
17. Cox D.R. Regression model and life tables (with discussion). J. R. Stat. Soc. B. 34 (1972) 187-219
18. Calhoun E., Welshman E., Chang C.H., Lurain J.R., Fishman D.A., Hunt T.L., et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systematic chemotherapy. Int. J. Gynecol. Cancer 13 (2003) 741-748
19. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 (2004) 2159-2166
20. Kopec J.A., Land S.R., Cecchini R.S., Ganz P.A., Cella D., Costantino J.P., et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J. Supportive Oncol. 4 (2006) W1-W8
21. Moore D., Donnelly J., McGuire W., Almadrones L., Cella D.F., Herzog T.J., et al. Limited access trial using amifostine for protection against cisplatin and 3-hour paclitaxel-included neurotoxicity: a phase II study of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 4207-4213
22. Hamilton C.A., Liou W.S., Osann K., Berman M.L., Husain A., Teng N.N., et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Intl. J. Radiat. Oncol. Biol. Phys. 63 (2005) 839-844
23. Martin J.D., Gilks B., and Lim P. Papillary serous carcinoma - a less radio-sensitive subtype of endometrial cancer. Gynecol. Oncol. 98 (2005) 299-303
24. Dede M., Yenen M.C., Goktolga U., Duru N.K., Guden M., Dilek S., et al. Is adjuvant therapy necessary for peritoneal cytology-positive surgical-pathologic Stage I endometrial cancer? Preliminary results. Eur. J. Gynaecol. Oncol. 25 (2004) 591-593
25. Tebeu P.M., Popowski G.Y., Verkooijen H.M., Casals J., Ludicke F., Zeciri G., et al. Impact of peritoneal cytology on survival of endometrial cancer patients treated with surgery and radiotherapy. Br. J. Cancer 89 (2003) 2023-2026